Business Context and Reporting Period
This Form 8-K is a current report filed by Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc., as indicated in the metadata) on April 2, 2010. The registrant is incorporated in Delaware and maintains its principal executive offices in Petaluma, California.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is a specific compensatory payment.
- Compensatory Payment: A one-time cash bonus of $100,000 was granted to Hojabr Alimi, Chairman of the Board and Chief Executive Officer.
Material Changes
The report discloses a material change regarding executive compensation under Item 5.02. The $100,000 bonus was awarded to partially compensate Mr. Alimi for financial sacrifices and personal debts incurred during the early years of building the company. No other material changes to operations or financial status are reported in this document.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future outlook, or discussion of risks and contingencies. The document is strictly limited to reporting the executive bonus and referencing an existing employment agreement dated January 1, 2004.
Key Facts for Investor Verification
- Verify the company name: The filing is for Oculus Innovative Sciences, Inc., not Sonoma Pharmaceuticals, Inc.
- Confirm the nature of the $100,000 payment as a retroactive bonus for past personal financial sacrifices rather than performance-based compensation.
- Note that this 8-K does not contain quarterly or annual financial results; investors should refer to 10-K or 10-Q filings for financial performance data.